Anastrozole
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
| |
| Anastrozole
| |
| Systematic (IUPAC) name | |
| 2-[3-(1-cyano-1-methyl-ethyl)- 5-(1H-1,2,4-triazol-1-ylmethyl)phenyl]- 2-methyl- propanenitrile | |
| Identifiers | |
| CAS number | |
| ATC code | L02 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C17H19N5 |
| Mol. mass | 293.366 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 83-85% |
| Protein binding | 40% |
| Metabolism | 85% hepatic |
| Half life | 72 hours |
| Excretion | 11% renal |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
Rx only (U.S.) |
| Routes | oral |
|
WikiDoc Resources for Anastrozole | |
|
Articles | |
|---|---|
|
Most recent articles on Anastrozole Most cited articles on Anastrozole | |
|
Media | |
|
Powerpoint slides on Anastrozole | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Anastrozole at Clinical Trials.gov Clinical Trials on Anastrozole at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Anastrozole
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Anastrozole Discussion groups on Anastrozole Patient Handouts on Anastrozole Directions to Hospitals Treating Anastrozole Risk calculators and risk factors for Anastrozole
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Anastrozole | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Anastrozole (INN, trade name: Arimidex®) is a drug indicated in the treatment of breast cancer in post-menopausal women. It is used both in adjuvant therapy (i.e. following surgery) and in metastatic breast cancer. It has the effect of decreasing the amount of estrogens that the body makes.
Anastrozole belongs in the class of drugs known as aromatase inhibitors. It inhibits the enzyme aromatase, which is responsible for converting androgens (produced by women in the adrenal glands) to estrogens.
The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial represents a long-term follow-up study of 9366 women with localized breast cancer who received either anastrozole, tamoxifen, or both.[1] After more than 5 years the group that received anastrozole had significantly better clinical results than the tamoxifen group. The trial suggested that anastrozole is the preferred medical therapy for postmenopausal women with localized breast cancer that is estrogen receptor positive.
Usage for men
While officially indicated for women, this drug has proven effective in the off-label use of reducing estrogens (in particular and more importantly, estradiol) in men. Excess estradiol in men can cause benign prostatic hyperplasia, gynecomastia, and symptoms of hypogonadism. Some athletes and body builders will also use anastrozole as a part of their steroid cycle to reduce and prevent symptoms of excess estrogens; in particular, gynecomastia and water retention.
Study data currently suggests that dosages of 0.5mg to 1mg a day reduce serum estradiol by about 50% in men, which differs from the typical reduction in postmenopausal women. However the reduction may be different for men with grossly elevated estradiol (clinical data is currently lacking).
Usage for children
This drug is frequently used in the treatment of growth disorder affected children to stop or slow the onset of puberty. The treatment of the growth disorder is through hormones which may trigger the early onset of puberty (precocious puberty). At the onset of puberty the bone growth plates begin to close. This can occur in children as young as 5 years old so for children severely behind in growth, the opportunity for increased growth is diminished. Arimidex is shown to slow or stop this process.
References
External links
it:Anastrozolo
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
